Background. Tigecycline is effective in the treatment of complicated skin/skin-structure infection (cSSSI), complicated intraabdominal infection (cIAI), and community-acquired bacterial pneumonia (CAP), but its efficacy in subjects with secondary bacteremia is unknown.
. Bacteremia with an identifiable source is termed secondary bacteremia and effective therapy directed against this source is believed to be required for proper treatment [4] .
Tigecycline, a tetracycline derivative antibiotic with activity against gram-positive, gram-negative, and anaerobic organisms, has been shown to be effective in the treatment of complicated skin/skin-structure infection (cSSSI), complicated intraabdominal infection (cIAI), and community-acquired bacterial pneumonia (CAP) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Pharmacokinetic evaluations of tigecycline demonstrate a large volume of distribution and low serum levels [31, 32] . Furthermore, tigecycline demonstrates mainly bacteriostatic antibacterial activity [33] . In light of these data, the use of tigecycline in subjects with bacteremia has been questioned, particularly in cases in which the minimum inhibitory concentration (MIC) of the pathogen approaches known serum tigecycline concentrations [34] [35] [36] . To address this question, we identified clinically evaluable subjects who presented with secondary bacteremia over the course of 6 prospective, multinational phase III clinical trials specific to the diagnoses of cIAI, cSSSI, and CAP, as well as 2 studies of tigecycline use in the context of persons with cIAI, cSSSI, and CAP and infection with drug-resistant pathogens [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .
METHODS
Data were derived from 8 phase III multicenter trials of tigecycline, 7 of which were randomized, double-blind, active-controlled, comparative trials and 1 of which was an open-label noncomparative trial. Studies were performed in multiple countries worldwide. Detailed descriptions of these studies have been reported elsewhere [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . In brief, for 6 of the trials, adult subjects who met specified criteria for cSSSI (2 studies), cIAI (2 studies), or CAP (2 studies) who required initial intravenous antibiotic therapy were treated with tigecycline or appropriate active comparator for 3 to 14 days. For the remaining 2 trials, subjects with serious infection with drugresistant bacteria (vancomycin-resistant Enterococcus or meth- were treated with tigecycline for 7-28 days; these studies enrolled subjects with the diagnoses of cIAI, cSSSI, CAP, hospitalacquired pneumonia, or primary bacteremia. Clinical responses at the test-of-cure assessment and safety parameters were evaluated. Each center received approval from its institutional review board or independent ethics committee, and all subjects provided written informed consent. Studies were conducted in accordance with the guidelines for Good Clinical Practices and the ethical principles of the Declaration of Helsinki.
For the current investigation, subjects enrolled for treatment of an active cSSSI, cIAI, and CAP found to have bacteremia at baseline were identified from the clinically evaluable populations of the 8 studies. Subjects defined as clinically evaluable were those who met baseline inclusion/exclusion criteria, received sufficient treatment to determine cure or failure, and had a clinical evaluation at test-of-cure assessment of "cure" or "failure." Bacteremic subjects were identified using a computerized search of study-specific Wyeth Pharmaceuticals databases for subjects with a pathogen isolated from culture with "blood' or "blood isolate" as a source and cross-referenced with historical summaries. Subjects with a sole fungal pathogen or a sole organism considered likely to be a contaminant (primarily coagulase-negative staphylococci, diphtheroids, and Bacillus species) were excluded. Data were examined for blood cultures positive after 124 h of therapy with the original infecting species (termed "persistent bacteremia") or a new species sensitive to test article (termed "breakthrough bacteremia"). The outcome for each subject was determined using the clinical cure/failure response for the primary diagnosis as provided by the treating physician at the time of the original studies. Cure was defined as resolution of the clinical signs and symptoms of infection with no further need for antibiotic therapy or source control. Criteria for failure included lack of clinical response or need for additional antibiotic therapy, initial recovery followed by deterioration, study withdrawal due to an adverse event, or death due to the infection being studied. The primary efficacy variable was the number and percentage of cures at the test-of-cure assessment as provided for the primary diagnosis among subjects with bacteremia treated with tigecycline versus comparator.
Safety evaluations including vital signs, electrocardiography, hematology and biochemistry laboratory evaluations, adverse events, and deaths as reported in the primary studies were examined.
Baseline demographics, safety measures, and efficacy rates were compared between groups using 1-way analysis of variance, the 2-tailed Fisher exact test, or the x 2 analysis where appropriate, as determined by Wyeth Programming and Biostatistics. Statistical significance was ascribed at . P ! .05
RESULTS

Subjects.
A search of the 8 phase III trial databases included for this analysis identified 239 clinically evaluable subjects with bacteremia at their baseline evaluation. Removal of likely clinical contaminants and subjects enrolled for treatment of diseases other than cIAI, cSSSI, or CAP left 170 clinically evaluable ). A P p .009 small number of subjects in both treatment arms received at least 1 dose of an unscheduled, nonstudy antibiotic during their treatment (9 [9.9%] of 91 subjects in the tigecycline arm vs 7 [8.9%] of 71 subjects in the comparator arm;
). Removal P 1 .99 of these subjects did not change the result of overall efficacy (not shown). There was no statistically significant betweengroup difference in the proportion of subjects who received nonstudy antibiotics after treatment, or in the receipt of any other nonstudy class of medication, including those for nausea and vomiting (data not shown).
Clinical efficacy. This study examined 170 subjects with secondary bacteremia, 91 (54%) of whom received tigecycline and 79 (46%) of whom received comparator antimicrobials. Complete efficacy results are provided in Table 2 . Treatment with tigecycline was successful in 74 (81.3%) of 91 tigecycline recipients versus 62 (78.5%) of 79 subjects treated with comparators (
). Clinical cure rates by primary disease state P 1 .99 were similar between the 2 treatment groups for each of the 3 primary disease states analyzed (for cIAI, ; for cSSSI, P p .786 ; for CAP, ). Analysis of cure rates by sex, age, P 1 .99 P p .279 creatinine clearance, presence or absence of diabetes, infection site, Fine score, and Acute Physiology and Chronic Health Evaluation (APACHE) score revealed no significant between-group differences.
Several pathogens were present in sufficient numbers to permit examination of efficacy based upon their presence in blood. Results are presented in Table 3 ). Ten of these organisms were classified as MRSA P 1 .99 on the basis of oxacillin sensitivity (MIC, 14 mg/mL). Five (83%) of 6 subjects treated with tigecycline experienced clinical cure, compared with 3 (75%) of 4 subjects treated with comparators. All comparator-treated subjects infected with MRSA were treated with vancomycin. Similarly, 43 subjects presented with pneumococcal bacteremia (24 tigecycline recipients and 19 recipients of comparators, mainly levofloxacin [18 of 19] Table 4 . There was no apparent trend towards lower cure rates in pathogens with higher tigecycline MICs than in those with lower MICs. Among S. aureus, MIC values were available on 20 of 20 tigecycline-treated subjects. The MICs of tigecycline ranged from 0.12 to 0.5 mg/mL, with an overall mode of 0.12 mg/mL (9 of 20). Of 11 isolates treated with vancomycin, MICs ranged from 1 to 4 mg/mL, with a mode of 1.0 mg/mL (9 of 11). Data was not available for 1 isolate treated with vancomycin.
Tigecycline MICs among S. pneumoniae ranged between 0.03 and 0.12 mg/mL, with 0.06 mg/mL being the most common result (20 of 23) . The MIC range of the levofloxacin-treated isolates fell within 1 dilution, 0.5-1.0 mg/mL (1.0 mg/mL for 16 of 18 isolates). Of the isolates included in the gram-negative efficacy analysis (defined above), MICs were available for all 30 isolates treated with tigecycline, providing an MIC range of 0.12-2.0 mg/mL and a modal value of 0.5 mg/mL. Of the 23 subjects given comparator antibiotics, 20 of 23 received imipenem. MICs of imipenem ranged from 0.12 to 0.5 mg/mL, with 0.12 mg/mL being most common (13 of 20) .
Streptococcus pyogenes
Tigecycline … 1/1 … … … … … … … Vancomycin … … … … 1/1 … … … …
Enterococcus faecalis
Tigecycline … … 3/3 … … … … … … Imipenem … … … … … 1/2 … 0/1 … Enterococcus faecium: tigecycline … 1/1 … … … … … … … Escherichia coli Tigecycline … … 2/3 3/4 2/4 … … … … Imipenem … … 10/11 a 1/1 … … … … …
Klebsiella pneumoniae
Ten subjects met the definition of persistent bacteremia; additional details of the clinical cases are provided in Table 5 . Of the 9 tigecycline-treated subjects, 5 had their final positive blood culture result 24-48 h after the start of therapy, and the remaining 4 had positive culture results 72 hours to 12 days after the first dose. Six subjects (66.7%) continued to receive tigecycline therapy without additional antibiotic treatment and achieved clinical cure of their infection. The single comparator subject with persistent bacteremia received imipenem for cIAI Subject was a 62-year-old woman who developed a pelvic abscess following hemicolectomy for colon carcinoma; exploration at the time of enrollment revealed dehiscence at the anastomosis; blood cultures positive for E. faecalis remained positive on day 4 of treatment; after 10 days of treatment, the patient was taken back to the OR for abdominal revision, and clinical failure was declared the following day; case was considered a "failure of source control" by the independent surgical review board and had positive blood culture results at day 4 of therapy in the context of an anastomotic leak; this subject was classified as having clinical failure. Two subjects experienced breakthrough bacteremia (1 tigecycline recipient and 1 person who was treated with a comparator). Cultured organisms included Enterococcus faecalis in the tigecycline-treated subject (MIC of tigecycline, 0.12 mg/mL) and Burkholderia cepacia in a subject who received imipenem (MIC of imipenem, 2.0 mg/mL). Both subjects were considered to have had clinical cure of their original infections. Subject was a 76-year-old woman without significant prior history enrolled with spontaneous abscess of the left thigh; subject underwent abscess incision, and TGC was initiated on day 1; cultures of blood and abscess samples were positive for E. coli; results of follow-up cultures of blood and skin samples were positive on the second day of therapy; subject was considered to be clinically cured after 9 days of therapy and remained cured at TOC on study day 29 10 cSSSI/TGC 3 Enterobacter aerogenes 1 Yes Cure Subject was a 43-year-old woman without significant medical history enrolled with a major abscess in the right inguinal area; the abscess was incised, and cultures of blood and abscess fluid specimens were positive for E. aerogenes; blood culture results remained positive on the second day of therapy; by day 8 of therapy, most signs and symptoms of infection resolved, and subject was considered to be clinically cured; the subject remained cured at the TOC visit on day 29
NOTE. APACHE, Acute Physiology and Chronic Health Evaluation; CAP, community-acquired pneumonia; cIAI, complicated intraabdominal infection; COPD, chronic obstructive pulmonary disease; cSSSI, complicated skin and skin-structure infection; CVC, central venous catheter; HTN, hypertension; IMI, imipenem; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus; OR, operating room; PVD, peripheral vascular disease; TGC, tigecycline; TOC, test of cure. a APACHE II scores are shown, unless otherwise indicated. b Fine score.
Safety. There were no significant between-group differences in subjects reporting serious adverse events, treatmentemergent adverse events, adverse events leading to discontinuation of treatment, or laboratory and vital sign measures of potential clinical importance while receiving therapy (data not shown).
Deaths were equally distributed among these subjects, with 2 deaths (2.2%) in the tigecycline group and 2 deaths (2.5%) in the comparator group ( ). The APACHE II scores for P 1 .99 the tigecycline subjects were 13 and 16, whereas those for the comparator subjects were 6 and 19. Both of the subjects who received tigecycline were enrolled as part of the 309 "resistant pathogens" study, a study that included subjects who were more severely ill at baseline. The first subject was a 72-year-old woman enrolled after 1.5 months of hospitalization for necrotizing pancreatitis. She was considered to be in septic shock with multiorgan failure at the time of enrollment. The second subject died with a persistent duodenal suture leak and localized peritonitis following treatment for a perforated ulcer. Of the comparator-treated subjects, 1 had an unexplained sudden death 3 weeks after completion of a course of imipenem for cIAI. The second subject died of complications of tension pneumothorax, sepsis, and an intracerebral hemorrhage 5 days after enrollment and randomization to receive imipenem for cIAI. None of the adverse events with an outcome of death for these 4 subjects were considered "related" to test article by the principal investigators.
DISCUSSION
Bacteremia is an event that establishes a subject with severe disease and at risk for poor outcomes; thus, the performance of an antibiotic in this setting is an important measure of efficacy [1, 4, 37, 38] . Tigecycline is an antibiotic derived from tetracycline with a broad spectrum of in vitro activity that has demonstrated clinical efficacy in the treatment of cIAI, cSSSI, and CAP [21] [22] [23] [24] [25] [26] [27] [28] . Several recent publications have described individual institutional case series of tigecycline use in bacteremia with varying results [36, [39] [40] [41] [42] [43] . These series are generally retrospective, noncomparative reviews of tigecycline use in bacteremia from Acinetobacter baumannii or other resistant gramnegative organisms in subjects with a variety of primary infection sites and concomitant treatments. To date, no systematic analysis has examined tigecycline's efficacy in subjects presenting with bacteremia in the setting of controlled trials. The current retrospective analysis found no difference in rates of clinical cure between tigecycline (81.3%) and comparator (78.5%). Tigecycline's clinical efficacy was similar to comparators regardless of the primary site of disease, infecting pathogen, and without a demonstrable difference in failure rates across susceptible MICs, as defined by the US Food and Drug Administration (FDA). Taken together, these data have implications pertinent to concerns surrounding tigecycline's efficacy following from the low serum concentrations and bacteriostatic mechanism of action.
Serum antibiotic levels are used as a readily measurable surrogate for antibiotic levels at the site of infection and contribute to several pharmacodynamic parameters potentially predictive of clinical success [44] . These include time above the MIC (T1MIC), area under the antibiotic concentration curve to MIC ratio (AUC:MIC), and concentration maximum to MIC ratio (C max :MIC) [45] . However, serum levels are relevant for antibiotics and infections where serum levels (ie, the central compartment) correlate with the tissue compartment at the site of infection [46] -characteristics not relevant to tigecycline [47] .
Studies have defined the AUC:MIC ratio as the parameter that best correlates with tigecycline efficacy [33] . In the current analysis, clinical efficacy in the setting of bacteremia resulting from 3 distinct sites of infection (lung, abdomen, and skin/soft tissues) was examined. Informative, published pharmacodynamic data are available for each of these disease states. The tigecycline C max in cantharidin-induced skin blister fluid following standard dosing of tigecycline was 273 ng/mL, compared with a serum C max of 819 ng/mL [48] . In an exposure response analysis of subjects enrolled in both phase II and phase III studies of tigecycline for treatment of cSSSI, calculated AUC 24 following standard dosing of tigecycline was 5.39 mg ϫ h/mL [49] . The mean AUC:MIC ratio ‫ע(‬ standard deviation) was , which proved to be significantly predictive of both 32.5 ‫ע‬ 24.1 clinical as well as microbiological success. Using Monte Carlo simulation, the probabilities of AUC:MIC breakpoint target attainment for S. aureus with MICs of 0.25 mg/mL, the most commonly observed MIC for S. aureus in this analysis, were 94.13% and 74.5%, respectively [33] . Similar analyses are available in the setting of cIAI and CAP [50, 51] . These results are consistent with the clinical cure rates observed in this analysis.
An additional issue raised with respect to the use of tigecycline in the treatment of bacteremia is its bacteriostatic mechanism of action. Antibiotics classified as bactericidal in vitro are considered to offer more rapid reduction in bacterial load, a desirable effect in bacteremic subjects who may be critically ill. The classification of antibiotics as one or the other is not always straightforward or reproducible and may vary by laboratory, testing methodology, and organism [44] . For example, although tigecycline is generally considered to be bacteriostatic, several studies report in vitro bactericidal activity against certain organisms, including S. pneumoniae and Legionella pneumophila [20, 52, 53] . In addition, other variables affecting clinical outcome such as host immunity, source control, and antibiotic site penetration may obscure measurable clinical differences based on in vitro bactericidal activity [44] . The efficacy of tigecycline demonstrated in this analysis does not indicate that its bacteriostatic action compromises its efficacy in subjects with secondary bacteremia.
In the analysis of "persistent bacteremia", a greater number of subjects treated with tigecycline versus comparator had positive blood cultures after 24 hours of therapy. It should be stated that the timing of follow-up blood cultures was not mandated by the study protocols and that the investigators were not asked to send the results of negative blood cultures. Thus, it is not possible to determine if this observation is due to true pharmacokinetic/pharmacodynamic properties of tigecycline or uncontrolled postrandomization events. Persistent bacteremia was noted in 3 patients presented in a retrospective review of tigecycline use in serious gram negative infections [43] . All organisms (A. baumannii, K. pneumoniae, and E. coli, 1 each) expressed MICs less than the tigecycline FDA breakpoint for Enterobacteriaceae. However, as noted by the authors, 2 of 3 patients had complications which likely contributed to the persistence, including retention of a central venous catheter with septic thrombophlebitis in one, and an infected anastamosis with pseudoaneurism in a recent heart transplant recipient.
Several cautionary points should also be made. It bears repeating that subjects were not enrolled for the treatment of bacteremia, but rather for cIAI, cSSSI, or CAP, and bacteremia was secondarily detected. Secondly, this study did not examine subjects with primary bacteremia, or bacteremia without an identifiable source of infection. Such a scenario is believed to portend a worse clinical outcome [4] . Tigecycline should not be used in this setting until controlled studies are performed. Finally, breakthrough bacteremia on therapy involving organisms resistant to tigecycline has been reported and associated with serious clinical consequences [36] . Thus, clinical response to treatment should be followed carefully whenever treating subjects with tigecycline.
This analysis has several limitations. First, this is a retrospective selection of subjects from clinical trials conducted at different times, with different protocols and indications. Studies 307 and 309 in particular included subjects of greater severity of illness, higher numbers of prior antibiotics failures, and limited (in Study 307, there was a 3:1 randomization tigecycline to the comparator) or no (Study 309) subjects randomized to comparator [29, 30] . Their inclusion reinforces the overall conclusions in so far as these subjects would be expected to skew results against tigecycline and in favor of comparator due to higher failure rates in a population with greater illness. An aggregate population of 170 subjects, while the largest sample of bacteremic subjects treated with tigecycline to date, provides limited power to detect differences between populations. This is particularly true for any attempted sub-analyses.
In conclusion, this analysis examined the clinical efficacy and safety of tigecycline in subjects presenting with concomitant bacteremia treated as part of 8 phase III multinational clinical studies. Tigecycline demonstrated cure rates similar to comparator and appears safe and effective in subjects presenting with bacteremia secondary to cIAI, cSSSI, and CAP.
